Understanding how intensive care unit (ICU) treatments align with a patient's priorities is crucial to evaluating and improving critical care. Yet, measuring this alignment is challenging because patient priorities evolve over time and are not systematically documented in electronic health records (EHR).

Obstructive sleep apnea (OSA) is associated with atrial fibrillation (AF), but this association varies by population and definitions of OSA and AF.

One approach to categorizing patients using chest computed tomography (CT) imaging manifestations of pulmonary sarcoidosis is into three classifications: fibrotic, non-fibrotic, or no parenchymal abnormality. We aimed to evaluate the relationships between these imaging subtypes and demographic and physiologic variables in a large group of sarcoidosis patients with chest CT.

Childhood interstitial lung diseases (chILDs) encompass a wide range of rare, chronic respiratory disorders, with pulmonary fibrosis (PF) being the clinical entity closely associated with mortality and morbidity.

Weight loss improves upper airway collapsibility in people with OSA. However, it is unclear how weight loss affects the other physiological traits (ie, endotypes) associated with OSA (loop gain, arousal threshold, and muscle compensation).

Targeted proximal hypoglossal nerve stimulation (THN, pHGNS) improved sleep-disordered breathing, sleep architecture, and quality of life (QOL) with a favorable safety profile over 1 year in the THN3 randomized, controlled trial. Herein, THN3 pHGNS 3-year safety and efficacy are profiled with reference to distal HGNS (dHGNS) from the STAR trial.

Persistent tachypnea of infancy (PTI), also known as neuroendocrine cell hyperplasia of infancy (NEHI), represents one of the most common childhood interstitial lung diseases. Despite its frequency, standardized management protocol is lacking, and long-term outcome data remain limited.

The historic National Lung Screening Trial (NLST) reported lung cancer-specific and all-cause mortality reductions associated with low-dose CT (LDCT) imaging, and nearly all relevant authoritative organizations established guidelines and policies supporting implementation and insurance coverage for individuals who meet eligibility criteria. The immediate challenge became translating results into community settings. Early translation showed substantial challenges to delivery of quality lung cancer screening (LCS). The Kentucky LEADS (Lung Cancer Education Awareness Detection Survivorship) Collaborative developed a comprehensive system to evaluate and support LCS delivery in community contexts with an emphasis on supporting rural and low-resource settings. The QUILS System 1.0 (Quality Implementation of Lung Cancer Screening) featured 4 key components: (1) the QUILS Index 1.0, a quantitatively driven evaluation system assessing quality across 6 essential LCS implementation domains; (2) the QUILS Audit and Feedback Process 1.0, a strategy for providing feedback and guidance to bridge the QUILS Index and the QUILS Resource Portal; (3) the QUILS Resource Portal 1.0, online tools and trainings that are directly tied to components within the QUILS Index 1.0; and (4) the QUILS Technical Assistance and Coaching 1.0, providing additional problem-solving and support upon request. The 6 essential domains included: (1) Screening Eligibility; (2) Radiology Operations; (3) Team Operations; (4) Prevention Efforts; (5) Patient Education; and (6) Community Outreach. To collect initial feedback and evaluate the QUILS System 1.0, the investigative team planned and conducted a rigorous evaluation of this initial framework across 10 sites in Kentucky over an 18-month period.

Patients with neuromuscular disease and other thoracic restrictive disorders are at increased risk of hypoxia during high-altitude travel due to an ineffective hypoxic ventilatory response. Efforts to identify clinical parameters that successfully predict the need for hypoxic challenge testing, a tool used to assess the risk of hypobaric hypoxia, and its outcomes in this population have been inconsistent and limited mainly to small, retrospective studies. Consequently, recommendations regarding the evaluation and management of these patients prior to high-altitude travel have been uncertain and differ across medical societies. We provide a clinical management algorithm for this patient population that draws on the available data.